Oncology, cancer prevention, tumor biology, and immunotherapy relevant to longevity
631 articoli
A Phase II NCI trial testing bintrafusp alfa in metastatic urothelial carcinoma was terminated after enrolling only 2 patients.
A bespoke DNA vaccine tailored to individual glioblastoma tumors shows promising immunological activity in one of oncology's hardest challenges.
Blocking CysLTR1 reprograms immunosuppressive neutrophils and reverses resistance to anti-PD1 checkpoint therapy in mice.
A newly identified lipid mediator may explain why immune cells fail to fight MASH-driven liver cancer, opening therapeutic targets.
MAIT cells appear to provide protective immune surveillance in Lynch syndrome carriers who haven't developed colorectal cancer, suggesting new risk stratification tools.
A comprehensive review in CA Cancer J Clin maps the molecular biology, treatment strategies, and equity gaps in high-grade serous ovarian cancer.
A Phase 1/2 trial explores combining KIR, PD-1, and CTLA-4 inhibitors to unlock stronger anti-tumor immunity.
A completed NCI trial evaluated advanced imaging and breast duct lavage in women with BRCA1/BRCA2 mutations to improve early cancer detection.
New research reveals how lung cancer subclones develop distinct immune evasion strategies, complicating immunotherapy response.
Memorial Sloan Kettering-led trials produced 11 new FDA-approved cancer therapies in a single year, spanning multiple tumor types.
New research reveals how corticotroph pituitary tumors develop resistance to temozolomide through clonal selection of high MGMT-expressing cells.
A multinational study of 4,913 patients finds EBRT delivers survival outcomes comparable to surgery and ablation for early hepatocellular carcinoma.
